OptimizeRx revenue, profitability improves
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging for the pharmaceutical industry, reported net income of $6,529 in the first quarter ended March 31, vs. a loss of …
Esperion posts first profit on royalty payments, nears market for cholesterol-busting drug
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) has provided a development update for its lead drug candidate, bempedoic acid, and financial results for the first quarter ended March 31. “The potential of …
Ann Arbor pharma screening firm in new partnership
ANN ARBOR—An Ann Arbor company that has developed a system to screen cancer patients to precision-designed treatments that will be most effective for them has a new clinical development collaboration …
OptimizeRx adds ‘chief commercial officer’
ROCHESTER—Officials at OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging in the pharmaceutical industry, announced the appointment of Stephen Silvestro to the new position of chief commercial officer. …
OptimizeRx integrates with EHR systems
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), the digital health messaging provider for the pharmaceutical industry, announced its latest platform integration with the health care industry’s leading acute electronic health record (EHR) systems, …
Saginaw company’s UTI drug approved in Canada
SAGINAW—Graminex L.L.C. announced it had received Health Canada approval for its PollenBerry Flower Pollen Extract. The approval came under Health Canada’s Natural and Non-prescription Health Products Directorate. PollenBerry is a …
Esperion expenses jump, but drug approval nears
ANN ARBOR – Esperion Therapeutics Inc. (NASDAQ:ESPR), the pharmaceutical startup developing a new cholesterol-fighting drug, reported a loss of $60 million in the fourth quarter, up from a loss of $37.9 …
New software to protect patient data in clinical trials
CANTON TWP. – TrialAssure, a clinical trial management software developer, announced the limited release of Anonymize.DS, an all-new software-as-a-service application that allows sponsors to anonymize clinical trial data automatically. “In …
OptimizeRx revenue rockets 75% in 2018
ROCHESTER — OptimizeRx Corp. (NASDAQ: OPRX), the Rochester-based provider of digital health messaging for the pharmaceutical industry, reported net income of $226,344 for the full year 2018, vs. a loss …
Millendo awards stock options
ANN ARBOR –Millendo Therapeutics Inc. (Nasdaq: MLND), the Ann Arbor pharmaceutical company developing treatments for endocrine diseases, announced the grant of inducement stock options to three new employees of the …